[go: up one dir, main page]

MX2020009991A - Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. - Google Patents

Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.

Info

Publication number
MX2020009991A
MX2020009991A MX2020009991A MX2020009991A MX2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A
Authority
MX
Mexico
Prior art keywords
disease
antibody
detecting
based methods
treating alzheimer
Prior art date
Application number
MX2020009991A
Other languages
English (en)
Inventor
Norbert Zilka
Eva Kontseková
Jozef Hanes
Andrej Kovác
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of MX2020009991A publication Critical patent/MX2020009991A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan aquí anticuerpos y fragmentos de unión a antígeno que se unen a tau fosforilada y desfosforilada, y métodos de uso para detectar y tratar la enfermedad de Alzheimer y otras tauopatías. También se incluyen métodos para determinar la etapa de la enfermedad de Alzheimer en un sujeto humano y monitorear la eficacia de una terapia anti-tau.
MX2020009991A 2018-03-28 2019-03-27 Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. MX2020009991A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2020009991A true MX2020009991A (es) 2020-10-14

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009991A MX2020009991A (es) 2018-03-28 2019-03-27 Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.

Country Status (12)

Country Link
EP (1) EP3774887A2 (es)
JP (1) JP2021520777A (es)
KR (1) KR20200144551A (es)
CN (1) CN112236452A (es)
AU (1) AU2019244481A1 (es)
BR (1) BR112020018868A2 (es)
CA (1) CA3095443A1 (es)
IL (1) IL277577A (es)
MX (1) MX2020009991A (es)
RU (1) RU2020135052A (es)
SG (1) SG11202008098TA (es)
WO (1) WO2019186276A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2021048619A2 (en) 2019-09-09 2021-03-18 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021403010A1 (en) * 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
CN115078736B (zh) * 2022-06-24 2025-03-25 佛山市观迪医疗器械有限公司 一种用于阿尔茨海默症的均相免疫检测试剂盒
CN119836437A (zh) * 2022-08-19 2025-04-15 舒泰神(加州)生物科技有限公司 特异性识别程序性细胞死亡1配体1的抗体及其用途
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用
WO2025119350A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 靶向Tau的特异性结合蛋白及其应用
WO2025160022A1 (en) * 2024-01-26 2025-07-31 Beckman Coulter, Inc. Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60320258T2 (de) 2002-07-12 2009-06-25 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
CA2791165C (en) 2002-12-03 2015-02-24 Blanchette Rockefeller Neurosciences Institute A conjugate comprising cholesterol linked to tetracycline
CA2511606A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
ES2614949T3 (es) * 2009-08-06 2017-06-02 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
UA115657C2 (uk) * 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
EP3578567A1 (en) * 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RS61431B1 (sr) * 2014-11-19 2021-03-31 Axon Neuroscience Se Humanizovana antitela na tau u alchajmerovoj bolesti
WO2017133673A1 (zh) * 2016-02-05 2017-08-10 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途

Also Published As

Publication number Publication date
WO2019186276A3 (en) 2020-02-27
WO2019186276A2 (en) 2019-10-03
CN112236452A (zh) 2021-01-15
SG11202008098TA (en) 2020-10-29
JP2021520777A (ja) 2021-08-26
WO2019186276A8 (en) 2020-10-15
IL277577A (en) 2020-11-30
BR112020018868A2 (pt) 2021-01-26
RU2020135052A (ru) 2022-04-29
KR20200144551A (ko) 2020-12-29
AU2019244481A1 (en) 2020-10-01
CA3095443A1 (en) 2019-10-03
EP3774887A2 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
MX2020009991A (es) Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CO2019008786A2 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CL2018001175A1 (es) Anticuerpos anti-il1rap, moleculas de union de antigenos bioespecificos que unen il1rap y cd3 y usos de los mismos.
BR112016030183A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
MX392396B (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
MX388142B (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
MX2018012856A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112020015498A8 (pt) Anticorpos anti-pd-1
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
EA202191666A1 (ru) Антитела к il-27 и их применение
EA201990895A1 (ru) Антитела к о1 и варианты их применения
CL2025000063A1 (es) Anticuerpos anti-abeta